Over the past few years, Big Pharma has experienced shrinking EBIT (earnings before interest and taxes) margins. The reasons behind this development are internal as well as external.
Internal reasons include the well-known patent-cliff, with many of the industry’s top revenue drivers losing exclusivity. In addition, Big Pharma companies have experienced a twofold innovation crisis. Given the vast...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?